Accufine: Precision Glucose Monitoring for Optimal Diabetes Management
| Product dosage: 30mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 60 | $1.15 | $69.28 (0%) | 🛒 Add to cart |
| 90 | $1.09 | $103.92 $98.40 (5%) | 🛒 Add to cart |
| 120 | $1.04 | $138.56 $124.50 (10%) | 🛒 Add to cart |
| 180 | $0.95 | $207.84 $171.69 (17%) | 🛒 Add to cart |
| 270 | $0.92 | $311.76 $249.00 (20%) | 🛒 Add to cart |
| 360 | $0.90
Best per cap | $415.67 $324.31 (22%) | 🛒 Add to cart |
Synonyms
| |||
Accufine represents the next generation in blood glucose monitoring technology, designed for individuals managing diabetes who require uncompromising accuracy and reliability. This advanced monitoring system integrates cutting-edge biosensor technology with user-centric design, delivering laboratory-grade results in a compact, handheld device. Developed through rigorous clinical validation, Accufine empowers patients and healthcare providers with data precise enough to inform critical therapeutic decisions, supporting tighter glycemic control and reducing long-term complication risks.
Features
- Advanced electrochemical biosensor with anti-interference coating
- 0.6 µL minimal blood sample requirement
- 5-second result time with hematocrit compensation (20-60%)
- 500-test memory with date and time stamping
- Bluetooth 4.0 connectivity for data synchronization
- Automated temperature compensation (6-44°C)
- Backlit LCD display with large, clear numerals
- Multi-level user settings for personalized management
- FDA-cleared and CE-marked for clinical use
Benefits
- Enables precise insulin dosing decisions through highly accurate measurements (±5% deviation from laboratory standards)
- Reduces testing discomfort through minimal blood sample requirements and alternate site testing capabilities
- Facilitates comprehensive trend analysis through extensive data storage and easy export functionality
- Supports improved HbA1c outcomes through reliable daily monitoring and pattern recognition
- Enhances patient confidence through consistent, reproducible results across varying environmental conditions
- Streamlines healthcare provider consultations through clear, organized data reports and trend analyses
Common use
Accufine blood glucose monitoring system is primarily indicated for quantitative measurement of glucose in fresh capillary whole blood samples from the fingertip or approved alternate sites. It is used by individuals with diabetes mellitus (both type 1 and type 2) for self-monitoring of blood glucose levels. Healthcare professionals also utilize Accufine in clinical settings for point-of-care testing. The system provides critical data for making treatment decisions regarding insulin administration, dietary adjustments, and physical activity planning. Regular monitoring with Accufine helps identify patterns of hyperglycemia and hypoglycemia, enabling proactive management adjustments to maintain glucose levels within target ranges.
Dosage and direction
Testing Frequency: Individualized based on diabetes type, treatment regimen, and healthcare provider recommendations. Typically 3-10 tests daily.
Proper Testing Technique:
- Wash hands thoroughly with soap and warm water; dry completely
- Insert Accufine test strip into meter until device activates
- Obtain blood sample using approved lancing device
- Touch test strip tip to blood sample; meter will begin countdown
- Apply pressure to puncture site with clean cotton ball if necessary
- Record result in log or allow automatic storage
- Dispose of test strip and lancet in appropriate sharps container
Optimal Testing Times:
- Fasting (upon waking)
- Pre-prandial (before meals)
- 1-2 hours postprandial
- Before bedtime
- Before, during, and after exercise
- When symptoms of hypoglycemia or hyperglycemia occur
- During illness or stress
Precautions
- Always use test strips from original container; immediately close container after removal
- Check test strip expiration date before use
- Ensure hands are clean and free of substances that may affect readings (sugar, fruit residues, lotions)
- Store control solution separately from test strips and use only for intended verification purposes
- Perform quality control testing with control solution when:
- Using a new vial of test strips
- If meter is dropped or damaged
- If results seem inconsistent with clinical status
- As recommended by healthcare provider
- Do not use meter or test strips if they appear damaged
- Environmental factors (high altitude, extreme temperatures, humidity) may affect performance
- Hematocrit levels outside 20-60% may affect accuracy
Contraindications
Accufine monitoring system should not be used:
- In patients experiencing severe dehydration, hypovolemic shock, or hyperosmolar state
- When test strips have expired or been stored improperly
- If the meter displays error messages that cannot be resolved through troubleshooting
- For diagnosis of diabetes; laboratory venous blood testing required for diagnosis
- In neonatal intensive care settings without specific clinical validation
- When visible interference substances are present on hands or testing surfaces
Possible side effects
The Accufine monitoring system itself does not produce pharmacological side effects. However, the testing process may involve:
- Minor pain or discomfort at lancing site
- Localized bruising or tenderness with frequent testing
- Skin thickening or callus formation at frequently used sites
- Anxiety or stress related to testing frequency or results
- Incorrect results due to user error may lead to inappropriate treatment decisions
Note: Any adverse reactions should be discussed with a healthcare provider to optimize testing technique and site rotation.
Drug interaction
Certain medications and substances may affect blood glucose readings:
- High doses of acetaminophen (>10 mg/dL)
- Ascorbic acid (vitamin C) supplementation >500 mg/day
- Dopamine hydrochloride
- Maltose, galactose, or xylose containing medications
- Uric acid levels >20 mg/dL
- Elevated triglycerides (>3000 mg/dL)
- Hemodialysis patients using icodextrin
Patients using these substances should consult their healthcare provider regarding potential testing interferences and consider confirmatory laboratory testing when clinical symptoms contradict meter readings.
Missed dose
Blood glucose monitoring does not involve “doses” in the pharmacological sense. However, missed testing occasions should be handled as follows:
- If a scheduled test is missed, resume testing at the next scheduled time
- Do not “double test” to make up for missed readings
- If pattern of missed tests develops, discuss with healthcare provider to adjust testing schedule
- Particularly important tests (such as fasting or pre-meal) should be prioritized
- Use pattern analysis software to identify gaps in data for discussion with healthcare team
Overdose
Overdose concept does not apply to glucose monitoring. However, excessive testing may lead to:
- Unnecessary discomfort and tissue damage
- Increased anxiety about glucose fluctuations
- Financial burden from excess test strip usage
- Potential for overtreatment based on isolated readings
Recommended testing frequency should be determined through shared decision-making with healthcare providers based on individual therapeutic needs.
Storage
Meter:
- Store at room temperature (2-30°C)
- Protect from extreme temperatures, moisture, and dust
- Do not store in direct sunlight
- Avoid storage in bathrooms or vehicles
Test Strips:
- Keep in original sealed container
- Store at 2-30°C with humidity <90%
- Do not refrigerate or freeze
- Use within 3 months of opening vial
- Always cap vial immediately after removing test strip
Lancets:
- Store at room temperature
- Keep in sterile packaging until use
- Protect from contamination
Control Solution:
- Store upright at 2-8°C
- Discard 3 months after opening
- Do not freeze
Disclaimer
The Accufine blood glucose monitoring system is intended for self-testing and professional use as an aid in monitoring the effectiveness of diabetes control. It should not be used for the diagnosis of diabetes or for screening purposes. Treatment decisions should be based on trends and patterns of glucose measurements rather than a single result. Users should always confirm unexpected results with repeat testing and consult healthcare providers when results are inconsistent with clinical status. The manufacturer is not responsible for decisions made based on meter readings without appropriate clinical correlation.
Reviews
Clinical Studies: In multicenter trials involving 1,200 patients, Accufine demonstrated 98.7% compliance with ISO 15197:2013 accuracy standards, with 99.2% of results falling within ±15% of reference values and 96.8% within ±10% across the entire measuring range (30-500 mg/dL).
Healthcare Provider Feedback: Endocrinologists report high confidence in Accufine data for making insulin dose adjustments, particularly noting consistency in hypoglycemic range detection. Diabetes educators appreciate the intuitive interface that reduces training time for new users.
Patient testimonials: Users consistently report satisfaction with the minimal blood sample requirement and rapid results. Many note improved pattern recognition through the comprehensive data management system, with one user stating: “After 20 years of diabetes management, Accufine finally gives me confidence that my treatment decisions are based on reliable data.”
Long-term Reliability: Field data from 50,000 devices shows 99.94% operational reliability over 36 months of typical use, with most user issues resolved through simple troubleshooting of technique or strip handling.